glp-1 agonists vision loss blindness Eye doctors warn drugs for diabetes and weight may pose rare risks, recommending regular checkups GLP 1 Blindness Risk |
Description
Here is the short answer: it depends on your concentration
The addition of spironolactone as a fourth-line therapy has been shown to significantly improve blood pressure control, as demonstrated in the PATHWAY-2 trial
They should not be used with DPP-4 inhibitors, in type 1 diabetes, or during pregnancy
M.BhattD
3 (2014): E418E426, 10.1210/jc.2013-3644
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
